ICPT Intercept Pharmaceuticals Inc.

61.59
-12.11  -16%
Previous Close 73.70
Open 68.01
Price To book 9.11
Market Cap 1545904134
Shares 25,099,921
Volume 11,856,341
Short Ratio 11.90
Av. Daily Volume 875,877

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 primary endpoint met - July 31, 2017. One patient death noted but DSMB noted unlikely to be related to OCA (company unsure).
Obeticholic acid (OCA) - CONTROL
NASH patients taking statins
Approved May 27 2016.
Obeticholic acid (OCA)
Primary biliary cirrhosis (PBC) - POISE
Phase 3 data due 1H 2019.
Obeticholic acid (OCA) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 2 data released July 31, 2017 - primary endpoint met.
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)

Latest News

  1. Arons & Arons, LLC. Announces Investigation on Behalf of Intercept Pharmaceuticals Inc. Investors
  2. Why Intercept Pharmaceuticals Is Sinking Again Today
  3. Versartis, Intercept Pharma Plunge into Friday’s 52-Week Low Club
  4. Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers
  5. Today's Research Reports on Stocks to Watch: Akari Therapeutics and Intercept Pharmaceuticals
  6. See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
  7. Analysts Say Buy Intercept Shares Despite Patient Deaths
  8. Why Intercept Pharmaceuticals Is Tumbling Today
  9. Why Intercept Pharmaceuticals, Transocean, and U.S. Steel Slumped Today
  10. Intercept Plunges On FDA's Warning Of Drug-Related Deaths
  11. Intercept: Why Is It Tanking?
  12. FDA Warns Doctors After 19 Deaths on Intercept Liver Drug
  13. Cramer's lightning round: I like Altria Group, but it's n...
  14. Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 8.6% Higher
  15. 3 Biotech Stocks I'd Buy Right Now
  16. ETFs with exposure to Intercept Pharmaceuticals, Inc. : September 13, 2017
  17. Intercept Pitfall Overblown After Drug-Related Deaths: Analyst
  18. Market Overreacts to Intercept Pharmaceutical Letter
  19. Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data